Test Bank for Basic and Clinical Pharmacology, 15th Edition by Bertram G. Katzung & Todd W. Vanderah | Verified Chapters 1-66 | Questions & Answers with USMLE-Style Rationales | Medical, Pharmacy & Nursing Exam Prep

INSTANT PDF DOWNLOAD—This is the official, comprehensive Test Bank for Basic and Clinical Pharmacology, 15th Edition by Bertram G. Katzung and Todd W. Vanderah, ISBN 9781260452310. Published by McGraw-Hill Education (2021), this resource is perfectly aligned with the world-renowned "Lange" pharmacology textbook used in medical, pharmacy, nursing, and allied health programs worldwide. As part of the acclaimed Lange medical book series, this test bank is the identical instructor resource used to create course examinations and is the most demanded study aid for students mastering the principles of pharmacology, drug mechanisms, and clinical applications while preparing for USMLE Step 1, NAPLEX, NCLEX-RN®, and other professional licensure exams . This verified test bank provides complete, chapter-by-chapter coverage of all 66 chapters with hundreds of exam-style questions including multiple-choice, clinical vignette-based questions, and USMLE-style case scenarios. Each question includes verified answers with detailed clinical rationales explaining the correct answer and clarifying common misconceptions, along with cognitive level tags, textbook page references, and clinical application notes . The structure mirrors the official textbook organization to ensure full curricular alignment and complete coverage for all health sciences programs . COMPREHENSIVE TOPIC COVERAGE INCLUDES: Section I: Basic Principles Chapter 1: Introduction: The Nature of Drugs & Drug Development & Regulation: Drug nomenclature, drug development process (preclinical, Phase I-IV), FDA regulation, orphan drugs, generic vs. brand-name medications, and pharmacotherapeutics . Chapter 2: Drug Receptors & Pharmacodynamics: Receptor theory, drug-receptor interactions, agonists vs. antagonists, dose-response relationships, potency, efficacy, therapeutic index, and signal transduction pathways . Chapter 3: Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Action: Absorption (bioavailability, first-pass effect), distribution (volume of distribution, protein binding), metabolism (Phase I and II reactions, CYP450 enzymes), excretion (renal, biliary), half-life, steady-state concentration, and dosing strategies . Chapter 4: Drug Biotransformation: Enzyme induction and inhibition, genetic polymorphisms in metabolism, and clinical implications of drug metabolism. Chapter 5: Pharmacogenomics: Genetic variation affecting drug response, personalized medicine, CYP450 polymorphisms, and pharmacogenetic testing. Section II: Autonomic Drugs Chapter 6: Introduction to Autonomic Pharmacology: Sympathetic vs. parasympathetic nervous system, neurotransmitter synthesis and release, receptor subtypes (alpha, beta, muscarinic, nicotinic). Chapter 7: Cholinoceptor-Activating & Cholinesterase-Inhibiting Drugs: Direct-acting cholinergic agonists, indirect-acting agents, cholinesterase inhibitors (neostigmine, physostigmine), clinical applications (myasthenia gravis, glaucoma), and cholinergic crisis. Chapter 8: Cholinoceptor-Blocking Drugs: Atropine, scopolamine, anticholinergic effects (dry mouth, urinary retention, constipation, blurred vision), and clinical uses. Chapter 9: Adrenoceptor Agonists & Sympathomimetic Drugs: Direct vs. indirect-acting sympathomimetics, alpha and beta receptor effects, epinephrine, norepinephrine, dopamine, dobutamine, albuterol, and clinical applications. Chapter 10: Adrenoceptor Antagonist Drugs: Alpha-blockers (prazosin), beta-blockers (propranolol, metoprolol, carvedilol), indications (hypertension, angina, heart failure), and adverse effects. Section III: Cardiovascular-Renal Drugs Chapter 11: Antihypertensive Agents: Diuretics, ACE inhibitors (lisinopril), ARBs (losartan), calcium channel blockers (amlodipine), beta-blockers, alpha-blockers, and treatment guidelines. Chapter 12: Vasodilators & the Treatment of Angina Pectoris: Nitrates (nitroglycerin), calcium channel blockers, beta-blockers, and management of stable and unstable angina. Chapter 13: Drugs Used in Heart Failure: Cardiac glycosides (digoxin), ACE inhibitors, ARBs, beta-blockers, diuretics, and aldosterone antagonists. Chapter 14: Agents Used in Cardiac Arrhythmias: Class I-IV antiarrhythmics (procainamide, lidocaine, amiodarone, verapamil), mechanism of action, and clinical indications. Chapter 15: Diuretic Agents: Thiazides, loop diuretics (furosemide), potassium-sparing diuretics (spironolactone), osmotic diuretics (mannitol), and adverse effects (electrolyte imbalances). Section IV: Drugs With Important Actions on Smooth Muscle Chapter 16: Histamine, Serotonin, & the Ergot Alkaloids: H1 and H2 receptor antagonists, antihistamines, serotonin (5-HT) receptors, ergot alkaloids (migraine treatment). Chapter 17: Vasoactive Peptides: Angiotensin, bradykinin, endothelin, and natriuretic peptides. Chapter 18: The Eicosanoids: Prostaglandins, Thromboxanes, Leukotrienes, & Related Compounds: Prostaglandin synthesis (COX pathway), NSAIDs, leukotriene modifiers (montelukast), and clinical applications. Chapter 19: Nitric Oxide: NO synthesis, mechanism of action, and clinical applications in vasodilation and erectile dysfunction. Chapter 20: Drugs Used in Asthma & Chronic Obstructive Pulmonary Disease: Beta2-agonists (albuterol, salmeterol), anticholinergics (ipratropium, tiotropium), corticosteroids, leukotriene modifiers, and monoclonal antibodies (omalizumab). Section V: Drugs That Act in the Central Nervous System Chapter 21: Introduction to the Pharmacology of CNS Drugs: Blood-brain barrier, neurotransmitter systems (GABA, glutamate, dopamine, serotonin, norepinephrine), and CNS drug classification. Chapter 22: Sedative-Hypnotic Drugs: Benzodiazepines (alprazolam, lorazepam), barbiturates, Z-drugs (zolpidem), mechanism of action (GABA-A receptor), and adverse effects (sedation, tolerance, dependence). Chapter 23: The Alcohols: Ethanol pharmacology, acute intoxication, withdrawal syndrome, and management of alcohol use disorder (disulfiram, naltrexone, acamprosate). Chapter 24: Antiseizure Drugs: Phenytoin, carbamazepine, valproate, levetiracetam, lamotrigine, gabapentin; mechanism of action, therapeutic drug monitoring, and status epilepticus management. Chapter 25: General Anesthetics: Inhalation anesthetics (sevoflurane, desflurane), IV anesthetics (propofol, etomidate, ketamine), and malignant hyperthermia. Chapter 26: Local Anesthetics: Lidocaine, bupivacaine; mechanism of action (sodium channel blockade), pharmacokinetics, and adverse effects (systemic toxicity). Chapter 27: Skeletal Muscle Relaxants: Centrally acting (baclofen, cyclobenzaprine), peripherally acting (neuromuscular blockers—succinylcholine, rocuronium), and clinical applications. Chapter 28: Pharmacologic Management of Parkinsonism & Other Movement Disorders: Levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and management of adverse effects (dyskinesia, on-off phenomenon). Chapter 29: Antipsychotic Agents & Lithium: First-generation antipsychotics (haloperidol, chlorpromazine), second-generation antipsychotics (clozapine, risperidone, olanzapine), EPS, tardive dyskinesia, neuroleptic malignant syndrome, and lithium for bipolar disorder. Chapter 30: Antidepressant Agents: SSRIs (fluoxetine, sertraline), SNRIs (venlafaxine), TCAs, MAOIs, atypical antidepressants (bupropion, mirtazapine), mechanism of action, adverse effects (serotonin syndrome), and clinical indications. Chapter 31: Opioid Agonists & Antagonists: Morphine, fentanyl, hydromorphone, oxycodone; mechanism (mu, kappa, delta receptors), adverse effects (respiratory depression, constipation), and reversal agents (naloxone). Chapter 32: Drugs of Abuse: Cocaine, amphetamines, cannabis, hallucinogens; pharmacology, addiction mechanisms, and treatment of substance use disorders. Section VI: Drugs Used to Treat Diseases of the Blood, Inflammation, & Gout Chapter 33: Agents Used in Cytopenias; Hematopoietic Growth Factors: Erythropoietin, filgrastim (G-CSF), and management of anemia and neutropenia. Chapter 34: Drugs Used in Disorders of Coagulation: Anticoagulants (heparin, warfarin, rivaroxaban, apixaban), antiplatelets (aspirin, clopidogrel), thrombolytics (alteplase), and reversal agents. Chapter 35: Agents Used in Dyslipidemia: Statins (atorvastatin, simvastatin), fibrates, bile acid sequestrants, niacin, ezetimibe, and PCSK9 inhibitors. Chapter 36: Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout: NSAIDs (ibuprofen, naproxen, celecoxib), acetaminophen, DMARDs (methotrexate, hydroxychloroquine), biologics (adalimumab), and gout medications (allopurinol, colchicine, febuxostat). Section VII: Endocrine Drugs Chapter 37: Hypothalamic & Pituitary Hormones: Growth hormone, vasopressin, oxytocin, and disorders of pituitary function. Chapter 38: Thyroid & Antithyroid Drugs: Levothyroxine, methimazole, propylthiouracil, and management of hyperthyroidism and hypothyroidism. Chapter 39: Adrenocorticosteroids & Adrenocortical Antagonists: Glucocorticoids (prednisone, hydrocortisone), mineralocorticoids (fludrocortisone), and management of adrenal insufficiency and inflammatory disorders. Chapter 40: The Gonadal Hormones & Inhibitors: Estrogens, progestins, androgens, oral contraceptives, hormone replacement therapy, and antiandrogens (finasteride). Chapter 41: Pancreatic Hormones & Glucose-Lowering Drugs: Insulin (rapid, short, intermediate, long-acting), oral antidiabetic agents (metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists), and management of diabetes complications. Chapter 42: Agents That Affect Bone Mineral Homeostasis: Bisphosphonates (alendronate), calcitonin, teriparatide, denosumab, and management of osteoporosis. Section VIII: Chemotherapeutic Drugs Chapter 43: Beta-Lactam & Other Cell Wall- & Membrane-Active Antibiotics: Penicillins, cephalosporins, carbapenems, monobactams, vancomycin; mechanism of action, adverse effects, and antimicrobial resistance. Chapter 44: Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, Streptogramins, Oxazolidinones, & Pleuromutilins: Doxycycline, azithromycin, clindamycin, linezolid; mechanism (protein synthesis inhibition) and clinical applications. Chapter 45: Aminoglycosides & Spectinomycin: Gentamicin, tobramycin, amikacin; mechanism, adverse effects (nephrotoxicity, ototoxicity), and therapeutic drug monitoring. Chapter 46: Sulfonamides, Trimethoprim, & Quinolones: Trimethoprim-sulfamethoxazole (TMP-SMX), ciprofloxacin, levofloxacin; mechanism and adverse effects. Chapter 47: Antimycobacterial Drugs: Isoniazid (INH), rifampin, ethambutol, pyrazinamide; management of tuberculosis (DOT), and monitoring for hepatotoxicity and peripheral neuropathy. Chapter 48: Antifungal Agents: Amphotericin B, fluconazole, voriconazole, caspofungin; mechanism and adverse effects. Chapter 49: Antiviral Agents: Antivirals for herpes (acyclovir), influenza (oseltamivir), hepatitis (interferon, direct-acting antivirals), HIV (HAART), and COVID-19. Chapter 50: Miscellaneous Antimicrobial Agents; Disinfectants, Antiseptics, & Sterilants: Agents for topical and environmental use. Chapter 51: Clinical Use of Antimicrobial Agents: Principles of antimicrobial selection, empiric therapy, culture and sensitivity testing, and antimicrobial stewardship. Chapter 52: Antiprotozoal Drugs: Chloroquine, artemisinin, metronidazole; management of malaria and parasitic infections. Chapter 53: Clinical Pharmacology of the Antihelminthic Drugs: Albendazole, mebendazole, ivermectin; management of helminth infections. Chapter 54: Cancer Chemotherapy: Alkylating agents, antimetabolites, antitumor antibiotics, plant alkaloids, targeted therapies (imatinib), monoclonal antibodies, and management of adverse effects (myelosuppression, nausea, alopecia). Chapter 55: Immunopharmacology: Immunosuppressants (cyclosporine, tacrolimus, mycophenolate), monoclonal antibodies, and vaccines. Section IX: Toxicology Chapter 56: Introduction to Toxicology: Occupational & Environmental: Principles of toxicology, dose-response, and environmental toxins. Chapter 57: Heavy Metal Intoxication & Chelators: Lead, mercury, arsenic poisoning; chelation therapy (EDTA, dimercaprol, succimer). Chapter 58: Management of the Poisoned Patient: Decontamination (activated charcoal, gastric lavage), antidotes, and supportive care. Section X: Special Topics Chapter 59: Special Aspects of Perinatal & Pediatric Pharmacology: Drug therapy during pregnancy (FDA pregnancy categories), lactation, pediatric dosing, and developmental considerations. Chapter 60: Special Aspects of Geriatric Pharmacology: Polypharmacy, pharmacokinetic and pharmacodynamic changes with aging, Beers Criteria, and medication safety in older adults. Chapter 61: Dermatologic Pharmacology: Topical agents, corticosteroids, retinoids, and management of acne, psoriasis, and dermatitis. Chapter 62: Drugs Used in the Treatment of Gastrointestinal Diseases: Antacids, H2 antagonists (ranitidine, famotidine), proton pump inhibitors (omeprazole), antiemetics (ondansetron), antidiarrheals, laxatives, and drugs for IBS and IBD. Chapter 63: Cannabinoid Drugs: Pharmacology of THC and CBD, clinical applications, and regulatory considerations . Chapter 64: Therapeutic & Toxic Potential of Over-the-Counter Agents: Common OTC medications (NSAIDs, antihistamines, cough and cold preparations), safety considerations, and interactions. Chapter 65: Dietary Supplements & Herbal Medications: St. John's wort, echinacea, ginkgo biloba, ginseng, kava; efficacy, safety, and drug interactions. Chapter 66: Rational Prescribing & Prescription Writing: Principles of rational drug therapy, prescription writing, and important drug interactions . Appendix: Vaccines, Immune Globulins, & Other Complex Biologic Products . DOCUMENT ACCESS: This test bank is available as an instant digital download (PDF) immediately upon purchase. Fully text-searchable, printable, and accessible anytime through your user account. Trusted by thousands of medical, pharmacy, nursing, and health sciences students for pharmacology course exams, USMLE Step 1 preparation, NAPLEX review, NCLEX-RN® success, and mastering the essential concepts of basic and clinical pharmacology .